P/E ratio for Evofem Biosciences (EVFM)
P/E ratio as of April 2024 (TTM): 0.0001
According to Evofem Biosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.000142779. At the end of 2022 the company had a P/E ratio of -0.0098.
P/E ratio history for Evofem Biosciences from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.0098 | -95.71% |
| 2021 | -0.2287 | -79.31% |
| 2020 | -1.11 | -60.4% |
| 2019 | -2.79 | 367.75% |
| 2018 | -0.5969 | 184.56% |
| 2017 | -0.2098 | -82.4% |
| 2016 | -1.19 | 169.16% |
| 2015 | -0.4427 | -95.21% |
| 2014 | -9.24 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -4.67 | -3,268,556.85% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -0.9953 | -697,191.31% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.